A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study

While the cardioprotective benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors have been established in patients with cardiovascular disease (CVD), their advantages over other anti-diabetic drugs at ...

Source: Cardiovascular Diabetology - February 2, 2021 Category: Cardiology Authors: Shigenori Hiruma, Fumika Shigiyama, Shinji Hisatake, Sunao Mizumura, Nobuyuki Shiraga, Masaaki Hori, Takanori Ikeda, Takahisa Hirose and Naoki Kumashiro Tags: Original investigation Source Type: research